What is Leerink Partnrs’ Forecast for OKUR FY2024 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for OnKure Therapeutics in a report issued on Thursday, December 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per share of ($3.89) for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q4 2024 earnings at ($1.10) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.65) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13).

A number of other research firms also recently commented on OKUR. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of OnKure Therapeutics in a research report on Friday, November 8th. Leerink Partners began coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective for the company. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Price Performance

NASDAQ:OKUR opened at $13.73 on Monday. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $77.60. The stock has a market capitalization of $45.90 million, a P/E ratio of -1.13 and a beta of 0.14. The company has a fifty day simple moving average of $16.73.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.